Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis

BACKGROUND: Nintedanib is a multi-kinase inhibitor approved for idiopathic pulmonary fibrosis (IPF); however, its efficacy and safety for patients with IPF and restricted pulmonary function remain unclear. Therefore, the objective of this study was to determine the efficacy and safety of nintedanib...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Senoo, Satoru, Miyahara, Nobuaki, Taniguchi, Akihiko, Oda, Naohiro, Itano, Junko, Higo, Hisao, Hara, Naofumi, Watanabe, Hiromi, Kano, Hirohisa, Suwaki, Toshimitsu, Fuchimoto, Yasuko, Kajimoto, Kazuhiro, Ichikawa, Hirohisa, Kudo, Kenichiro, Shibayama, Takuo, Tanimoto, Yasushi, Kuyama, Shoichi, Kanehiro, Arihiko, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2020
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7451511/
https://ncbi.nlm.nih.gov/pubmed/32853277
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0236935
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados